Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | ICMT | O60725 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163665 | 0.94 | AR (0.55) | ARPPARDPPARAICMTHTT | |
| SCHEMBL5440161 | 0.92 | AR (0.49) | ARPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7996217 | 0.88 | ALDH1A1 (0.50) | ARSMPD1PPARDPPARAICMT | |
| SCHEMBL15364954 | 0.85 | AR (0.49) | ARPPARDPPARAPDE4BPDE4A | |
| SCHEMBL1579372 | 0.85 | ALDH1A1 (0.54) | SMPD1HTTTSHRALDH1A1HPGD | |
| SCHEMBL523551 | 0.85 | MPO (0.54) | ARPPARDPPARAICMTLMNA | |
| SCHEMBL15869350 | 0.85 | TRPV4 (0.56) | ARPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1964286 | 0.85 | TRPV4 (0.56) | ARPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12694547 | 0.84 | AR (0.48) | ARPPARDPPARAPDE4BPDE4A | |
| SCHEMBL13126996 | 0.84 | TUBB1 (0.51) | ARPPARDPPARAPDE4BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617227-B2 | Process of preparing a quinazoline derivative | SCINOPHARM (CHANGSHU) PHARMACEUTICALS, LTD. (CN) | 2017-04-11 | — | — | US | disclosed |
| US-20160200688-A1 | Process of Preparing a Quinazoline Derivative | SCIANDA (CHANGSHU) PHARMACEUTICALS, LTD. (CN) | 2016-07-14 | — | — | US | disclosed |
| WO-2012083153-A1 | OLIGOMER-CONTAINING APREMILAST MOIETY COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-1824479-B1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARM BV (NL) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200688-A1 | Process of Preparing a Quinazoline Derivative | ABL1, EGFR, KRAS | AR 1761/4885SMPD1 4430/4885PPARD 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.